<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医麦客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-09T11:26:05+08:00</updated>
  <subtitle>医麦客是一个聚焦转化医学、精准医疗和生物制药的专业媒体平台，持续关注体外诊断、抗体药物、细胞治疗、基因治疗等细分领域。为新生物医药医疗领域的企业发声，推动企业和行业的快速发展。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>细胞治疗产业蓬勃发展，需要更加可靠、高效和灵活的生产管理平台丨医麦新观察</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/Ve-w7hq-oQB8aYe3TD1ZLQ</id>
    <link href="https://mp.weixin.qq.com/s/Ve-w7hq-oQB8aYe3TD1ZLQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>邀请函 | 2020年创新药物临床前研究学术研讨会</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/1Yq5zqQigEfR9EnByo0r6Q</id>
    <link href="https://mp.weixin.qq.com/s/1Yq5zqQigEfR9EnByo0r6Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>东曜药业公布ADC在研药物TAA013 I期研究结果丨医麦猛爆料</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/QvkEPDdd_33iubRmqoITnA</id>
    <link href="https://mp.weixin.qq.com/s/QvkEPDdd_33iubRmqoITnA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复盘ASH2020：聚焦BCMA CAR-T，自体、同种异体、非病毒载体、双靶点齐上阵丨医麦新观察</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/ha_MKgXUqbwY5GdWA_BAPw</id>
    <link href="https://mp.weixin.qq.com/s/ha_MKgXUqbwY5GdWA_BAPw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>最后两天优惠丨人类遗传资源与生物医药注册法规官方解读</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/M_Yuz1bp_iDmL-YZ2cRwCg</id>
    <link href="https://mp.weixin.qq.com/s/M_Yuz1bp_iDmL-YZ2cRwCg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>高力教授：ASCT治疗T细胞淋巴瘤（新桥）经验分享</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/XgYY3HVNe9zvrcgSKw5wPg</id>
    <link href="https://mp.weixin.qq.com/s/XgYY3HVNe9zvrcgSKw5wPg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>「峰客访谈」予果生物CEO夏涵：与时间、市场赛跑，抢夺mNGS领域排头兵</title>
    <updated>2020-12-09T09:06:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/Fgt2S52lGLTHPRufBOMILg</id>
    <link href="https://mp.weixin.qq.com/s/Fgt2S52lGLTHPRufBOMILg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>聚焦ASH 2020：ROR1 ADC赛道有何看点？丨医麦新观察</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/Grwgqk_X83trRxwYQl46sw</id>
    <link href="https://mp.weixin.qq.com/s/Grwgqk_X83trRxwYQl46sw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>科济生物BCMA CAR-T疗法正式纳入突破性治疗品种，ASH年会最新数据展现治疗R/R MM患者的巨大潜力丨医麦猛爆料</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/77jx-8pbgMw0moD_8xmYqg</id>
    <link href="https://mp.weixin.qq.com/s/77jx-8pbgMw0moD_8xmYqg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>920医院及新桥医院联合开展世界首例通用型CAR-T细胞治疗成人急性T淋巴细胞白血病丨医麦猛爆料</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/0yVcBBBF6ZbdwGajxjzlhg</id>
    <link href="https://mp.weixin.qq.com/s/0yVcBBBF6ZbdwGajxjzlhg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH 2020：再生元CD20/CD3双抗显示出积极的临床数据，以CAR-T细胞为潜在竞争对手丨医麦猛爆料</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/Wwb5ZlLYRaMM9c-zC0fVPw</id>
    <link href="https://mp.weixin.qq.com/s/Wwb5ZlLYRaMM9c-zC0fVPw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH 2020：亚盛医药公布抗耐药白血病新药HQP1351（奥瑞巴替尼）关键性注册II期研究的积极数据</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/Jeg4WBJ3ws9hMjU5z4w5lQ</id>
    <link href="https://mp.weixin.qq.com/s/Jeg4WBJ3ws9hMjU5z4w5lQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>梁爱斌教授：CAR-T细胞治疗血液肿瘤日趋成熟，临床研究及应用的规范性和科学性有待加强</title>
    <updated>2020-12-07T23:57:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/NtcTw21sVDkCo5dyBvlrng</id>
    <link href="https://mp.weixin.qq.com/s/NtcTw21sVDkCo5dyBvlrng" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>​ASH 2020：亘喜生物发表基于FasTCAR平台技术开发的首创BCMA/CD19双靶向CAR-T的首次人体试验数据</title>
    <updated>2020-12-06T23:29:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/Y7g4jpRhA8CnFjzG6pN35Q</id>
    <link href="https://mp.weixin.qq.com/s/Y7g4jpRhA8CnFjzG6pN35Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASH 2020：全球首次报道非病毒定点整合CAR-T (nvGT CAR-T)的人体临床研究结果丨医麦猛爆料</title>
    <updated>2020-12-06T23:29:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/B41O9fFvLXxCVRfAh9Duhg</id>
    <link href="https://mp.weixin.qq.com/s/B41O9fFvLXxCVRfAh9Duhg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>王军志院士：BNT162b2新冠核酸疫苗是疫苗研发国际合作的成功范例丨医麦新观察</title>
    <updated>2020-12-06T23:29:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/vParEZwHeRFZWPaVlcdsfA</id>
    <link href="https://mp.weixin.qq.com/s/vParEZwHeRFZWPaVlcdsfA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>重磅！提高肿瘤识别精确度，癌症大数据分析助力“智能”细胞疗法丨医麦黑科技</title>
    <updated>2020-12-06T23:29:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/E9Ra4OIB6kHyp2M0OxeFUA</id>
    <link href="https://mp.weixin.qq.com/s/E9Ra4OIB6kHyp2M0OxeFUA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>宋玉琴教授：CAR-T细胞治疗毒副作用处理（北肿）经验分享</title>
    <updated>2020-12-06T23:29:55+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/u-boaxn3CndgDwUyyacPtQ</id>
    <link href="https://mp.weixin.qq.com/s/u-boaxn3CndgDwUyyacPtQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>宾大团队发文：改善CAR-T治疗实体瘤的新策略，靶向PAK4重构肿瘤血管微环境丨医麦猛爆料</title>
    <updated>2020-12-06T10:16:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/aU6S1lnuzci9q8GbPqK6Ng</id>
    <link href="https://mp.weixin.qq.com/s/aU6S1lnuzci9q8GbPqK6Ng" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>科济生物在第62届ASH年会展示CT053 BCMA CAR-T细胞治疗多发性骨髓瘤最新治疗数据丨医麦猛爆料</title>
    <updated>2020-12-06T10:16:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/Ifub3k9P9V02BNYWIOPTWg</id>
    <link href="https://mp.weixin.qq.com/s/Ifub3k9P9V02BNYWIOPTWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>